Immutrix Overview

  • Founded
  • 2009

Founded
  • Status
  • Private

  • Employees
  • 22

Employees
  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $750K

  • Investors
  • 1

Immutrix General Information

Description

Developer of a medical device designed to remove inflammatory mediators and toxins from the blood. The company's device uses proprietary adsorbents and smart hollow-fiber membranes to efficiently and selectively remove a broad range of pro-inflammatory mediators from blood, enabling clinicians to offer rapid response treatments to remove toxins, poisons, and biological modifiers.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Devices and Supplies
Primary Office
  • 3620 Homestead Street
  • Rapid City, SD 57703
  • United States
+1 (605) 000-0000

Immutrix Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Immutrix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC 13-Jul-2020 $750K 0000 Completed Generating Revenue
4. Debt - PPP 10-Apr-2020 00000 000.00 Completed Clinical Trials - General
3. Later Stage VC 01-Oct-2018 00.000 000.00 Completed Clinical Trials - General
2. Later Stage VC 19-Jul-2016 $4.09M $7.99M Completed Clinical Trials - General
1. Seed Round 20-Oct-2015 $3.9M $3.9M 000.00 Completed Startup
To view Immutrix’s complete valuation and funding history, request access »

Immutrix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00 00.0 00.0 00 00.0 0.00
To view Immutrix’s complete cap table history, request access »

Immutrix Patents

Immutrix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3867638-A1 Adsorption and binding of plasma molecules and particles to carbon Pending 17-Oct-2018 000000000
AU-2019362006-A1 Adsorption and binding of plasma molecules and particles to carbon Pending 17-Oct-2018 000000000
CA-3116721-A1 Adsorption and binding of plasma molecules and particles to carbon Pending 17-Oct-2018 000000000
EP-3867638-A4 Adsorption and binding of plasma molecules and particles to carbon Pending 17-Oct-2018 000000000 0
US-20220120648-A1 Adsorption and binding of plasma molecules and particles to carbon Pending 17-Oct-2018 B01J20/20
To view Immutrix’s complete patent history, request access »

Immutrix Executive Team (6)

Name Title Board Seat Contact Info
Carol Rae Co-Founder, Co-Chief Executive Officer, President & Chairwoman
Jim Gibbons Co-Chief Executive Officer
Leroy Ketel Chief Financial Officer & Board Member
Jeff Barnes Co-Founder
You’re viewing 4 of 6 executive team members. Get the full list »

Immutrix Board Members (6)

Name Representing Role Since
Brent Phillips Immutrix Board Member 000 0000
Carol Rae Immutrix Co-Founder, Co-Chief Executive Officer, President & Chairwoman 000 0000
Craig Hansen Self Board Member 000 0000
Leroy Ketel Immutrix Chief Financial Officer & Board Member 000 0000
Stephanie Durso Immutrix Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »

Immutrix Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immutrix Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
SDR Ventures Venture Capital Minority 000 0000 000000 0
To view Immutrix’s complete investors history, request access »